GPCR Allostery: Unlock Hidden Mechanisms and Make Smarter Drug Decisions
- GPCR News
- 1 day ago
- 3 min read
Welcome back GPCR fans,
If your drug discovery strategy still relies on static GPCR models, you’re already behind. Allostery isn’t just an advanced concept—it’s essential to understanding efficacy, ligand bias, and receptor behavior in real-world systems.
That’s exactly what Terry’s Corner delivers this week: high-impact insight into GPCR allostery, crafted for pharmacologists and biotech scientists who need to translate mechanistic nuance into better decision-making.
🔍 This Week in Premium: Sneak Peek
Industry insights: Strategic biotech alliances (Chemspace/Enamine, Superluminal Medicines), Novartis financial leadership shakeup, and next-gen GPCR targeting platforms reshaping immunotherapy pipelines.
Upcoming events: GPCR-UK Network Meeting, neuroGPCR symposium, and Transatlantic ECI GPCR event—where discovery and collaboration intersect.
Career opportunities: Exclusive pharma and academic listings you won’t find on job boards—curated for translational scientists and GPCR specialists.
Must-read publications: CXCL12 dimer impact on AML migration, mechanosensitive behavior in GPCRs, and in vivo APLNR biosensor imaging.
Terry's Corner : Stop Chasing Affinity and Start Reading the System
In this week’s cornerstone Terry’s Corner lecture, Dr. Terry Kenakin reframes GPCRs as dynamic, allosteric sensors—far from static binding sites.
This is the lens that lets scientists anticipate drug effects, decode kinetic behavior, and optimize probe-dependent signaling.
What you’ll learn:
Reveal cryptic binding sites and time-dependent interactions. Some drugs take hours to reach equilibrium—not because of poor design, but because the system is fluid. Learn how to decode that fluidity.
Exploit probe dependence to shape precision pharmacology. Want to avoid off-target effects? Understand how GPCRs react differently depending on the probe.
Map dynamic receptor behavior to real-time decision-making. Allostery is not passive—it’s predictive. Leverage this model to stay ahead of therapeutic complexity.
To stay in the know on upcoming courses and AMA session, get the complementary Kenakin Brief, the weekly newsletter delivered directly to your inbox.
GPCR Signal Transduction Call for Papers: Define What Comes Next
Volume I was just the beginning with over 28K reads. As the GPCR field surges forward—from ligand bias to signaling diversity—the guest editors Dr. Lauren Slosky, Stuart Maudsley and Yamina Berchiche invite your insights for Volume II.
This is a chance to shape the next scientific consensus on how GPCRs work, signal, and fail.
Why this matters:
Secure your voice in the next chapter of GPCR science. Your work belongs in the core conversation—not buried in supplementary files.
Position your research for maximum visibility. This is where funders, peers, and biotech scouts are watching.
Contribute to an evolving field still rich with firsts. Volume II isn’t about repetition—it’s about redefining signal transduction.
📝 Manuscript summary deadline: 23 Sept 2025
📄 Submission deadline: 11 Jan 2026
Discovery On Target: Where the Next Decade of GPCR Drugs Begins
If you’re not attending the GPCR-focused sessions at Discovery On Target 2025, you’re missing where the field is headed. It’s the 20th anniversary—and the spotlight is squarely on kinetic modeling, allosteric frameworks, and targeting the “undruggable.”
🔥 Featured: Dr. Terry Kenakin on “The Kinetics of Allostery: The Added Benefits of Allosteric Function.”
Why you need to be there:
Learn how kinetic nuance shapes ligand design. Don’t just measure residence—understand it.
Access peer insights on allosteric modulators and biased ligands.
Join the conversation on computational targeting and next-gen selectivity.
What our community is saying
“I enjoy the breadth of questioning that goes beyond just the science, and reveals a bit about the scientists as individuals/mentors/people.” — Dr. GPCR Podcast Listener
Why Dr. GPCR Premium Membership Gives You an Edge
Premium delivers curated, noise-free intelligence every week: deep-dive expert lectures, classified industry news, priority event alerts, job opportunities, and insider commentary—designed to help you move faster, smarter.
If you work on GPCRs across translational pharmacology, drug development, or molecular pharmacology, this is your decision advantage. Our Premium Members don’t have to chase signals—they act on them.
FAQ: What You Get with Dr. GPCR Premium
🔹 What’s included?
The complete Weekly News digest, curated jobs, upcoming events, classified GPCR publications, exclusive on-demand expert frameworks, and member-only discounts.
🔹 Who is it for?
GPCR scientists, translational pharmacologists, biotech drug discovery teams, and decision-makers who need fast, curated, career-relevant intelligence to stay ahead.
🔹 Why now?
The pace of GPCR innovation is accelerating. Those acting on the right signals today will shape tomorrow’s breakthroughs—and avoid delays others won’t see coming.
Comments